 |
- Presented a roadmap to enhance screening reliability at the world's leading multidisciplinary HPV congress held in Portugal from March 16-19
- Demonstrated how self-collected samples for HPV testing can bridge gaps in cervical cancer screening and advance HPV screening goals
SEOUL, South Korea, March 20, 2025 /PRNewswire/ -- Seegene Inc., a global leader in total solution for PCR molecular diagnostics, presented its high-precision Human Papillomavirus (HPV) screening and full genotyping solutions at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) 2025 in Porto, Portugal from March 16-19.
The company showcased its expertise through an exhibition booth under the theme "Elevating Confidence in HPV Screening" and hosted symposium programs to emphasize accurate identification of high-risk HPV types related to cervical cancer is critical. Seegene's advanced solution enhances diagnostic accuracy, enabling timely and effective detection.
Seegene presented its flagship HPV diagnostic product lineup that are designed to simultaneously detect HPV genotypes responsible for cervical cancer and/or HPV-related cancer. This capability is crucial in identifying high-risk HPV types that are known to cause cervical cancer and detecting other genotypes that are associated with benign tumors.
At the Seegene symposium on March 16, leading clinical experts from Europe discussed strategies for integrating HPV testing into real-world clinical practice. The symposium underscored the critical role of HPV testing in the early detection of cervical cancer. Additionally, the experts highlighted the advantages of self-sampling, a method that enables individuals to collect their own samples. This approach not only streamlines the testing process but also promotes the broader adoption of HPV screening.
"Seegene's HPV testing solutions are designed to deliver accurate diagnostics and reliable testing capabilities in real-world clinical environments," said Daniel Shin, Executive Vice President and Chief Global Sales & Marketing Officer at Seegene.
Seegene's annual participation in EUROGIN is a testament to its commitment to advancing HPV screening and genotyping for the accurate diagnosis and prevention of cervical cancer. In July 2024, the company also took part in the Asia-Oceania Research Organization on Genital Infection and Neoplasia (AOGIN) 2024 held in Seoul.
According to the World Health Organization (WHO), Cervical cancer is the fourth most common cancer among women worldwide and the second leading cause of cancer-related deaths. In 2018, the WHO launched the 90-70-90 campaign to eliminate cervical cancer. The targets aim to achieve 90% HPV vaccination coverage among girls by the age of 15; 70% of women screened using high-performance tests by the age of 35 and 45; and treatment for 90% of women identified with pre-cancer and invasive cancer by 2030.
About Seegene
Seegene has more than 20 years of dedicated experience in R&D, manufacturing, and business related to syndromic real-time PCR technologies. This expertise was particularly highlighted during the COVID-19 pandemic when Seegene provided over 340 million COVID-19 tests to more than 100 countries worldwide. The core feature of Seegene's syndromic real-time PCR technology is the ability to simultaneously test for 14 pathogens that cause similar symptoms in a single tube with quantitative information.
Visit: Seegene.com and follow linkedin.com/company/seegene-inc
- Presented a roadmap to enhance screening reliability at the world's leading multidisciplinary HPV congress held in Portugal from March 16-19
- Demonstrated how self-collected samples for HPV testing can bridge gaps in cervical cancer screening and advance HPV screening goals
SEOUL, South Korea, March 20, 2025 /PRNewswire/ -- Seegene Inc., a global leader in total solution for PCR molecular diagnostics, presented its high-precision Human Papillomavirus (HPV) screening and full genotyping solutions at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) 2025 in Porto, Portugal from March 16-19.
The company showcased its expertise through an exhibition booth under the theme "Elevating Confidence in HPV Screening" and hosted symposium programs to emphasize accurate identification of high-risk HPV types related to cervical cancer is critical. Seegene's advanced solution enhances diagnostic accuracy, enabling timely and effective detection.
Seegene presented its flagship HPV diagnostic product lineup that are designed to simultaneously detect HPV genotypes responsible for cervical cancer and/or HPV-related cancer. This capability is crucial in identifying high-risk HPV types that are known to cause cervical cancer and detecting other genotypes that are associated with benign tumors.
At the Seegene symposium on March 16, leading clinical experts from Europe discussed strategies for integrating HPV testing into real-world clinical practice. The symposium underscored the critical role of HPV testing in the early detection of cervical cancer. Additionally, the experts highlighted the advantages of self-sampling, a method that enables individuals to collect their own samples. This approach not only streamlines the testing process but also promotes the broader adoption of HPV screening.
"Seegene's HPV testing solutions are designed to deliver accurate diagnostics and reliable testing capabilities in real-world clinical environments," said Daniel Shin, Executive Vice President and Chief Global Sales & Marketing Officer at Seegene.
Seegene's annual participation in EUROGIN is a testament to its commitment to advancing HPV screening and genotyping for the accurate diagnosis and prevention of cervical cancer. In July 2024, the company also took part in the Asia-Oceania Research Organization on Genital Infection and Neoplasia (AOGIN) 2024 held in Seoul.
According to the World Health Organization (WHO), Cervical cancer is the fourth most common cancer among women worldwide and the second leading cause of cancer-related deaths. In 2018, the WHO launched the 90-70-90 campaign to eliminate cervical cancer. The targets aim to achieve 90% HPV vaccination coverage among girls by the age of 15; 70% of women screened using high-performance tests by the age of 35 and 45; and treatment for 90% of women identified with pre-cancer and invasive cancer by 2030.
About Seegene
Seegene has more than 20 years of dedicated experience in R&D, manufacturing, and business related to syndromic real-time PCR technologies. This expertise was particularly highlighted during the COVID-19 pandemic when Seegene provided over 340 million COVID-19 tests to more than 100 countries worldwide. The core feature of Seegene's syndromic real-time PCR technology is the ability to simultaneously test for 14 pathogens that cause similar symptoms in a single tube with quantitative information.
Visit: Seegene.com and follow linkedin.com/company/seegene-inc
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Seegene Unveils HPV Genotyping Solution at EUROGIN 2025
In the news release, "International Healthcare Week Returns to Thailand in 2026 with Expanded Industry Reach", issued on 15 January 2026 by Informa Markets. over PR Newswire, we are advised by the company that the testimonial featured on behalf of i-SENS, South Korea., the name mentioned should read "Na Jiwoong, POC Division Head, i-SENS, South Korea." rather than "Haeun Jung, Global Marketing Manager, i-SENS, Korea" as originally issued inadvertently.
BANGKOK, Jan. 15, 2026 /PRNewswire/ -- International Healthcare Week is set to return to Thailand (8-10 July 2026, Queen Sirikit National Convention Center, Bangkok), bringing together the region's most influential health and wellness stakeholders. Organised by Informa Markets, this flagship event will co-locate three major exhibitions: CPHI South East Asia, WHX Bangkok (formerly Medlab Asia and Asia Health), and Medtec Southeast Asia. These events will unite cutting-edge pharmaceutical, medical device, medical laboratory and design and manufacturers of medical devices under one roof, attracting an expected 26,000+ visitors.
Demonstrating Informa's strong commitment to expanding and deepening industry networks, International Healthcare Week 2026 will feature over 1,000 leading local, regional and international exhibitors. This expansion underscores the event's vital role as a strategic platform to advance the health and wellness industry throughout Southeast Asia.
By uniting pharmaceutical, medical device, medical laboratory, and medical technology manufacturing, International Healthcare Week 2026 plays a critical role in accelerating regional healthcare integration and improving health outcomes for diverse communities. The event supports Southeast Asia's healthcare priorities, promoting sustainable development and advanced medical technologies that benefit the entire region.
The events' collaborative approach empowers stakeholders to share knowledge, build partnerships, and create scalable solutions tailored to the unique challenges faced by Southeast Asia countries. This cultivates a robust healthcare ecosystem that enhances access, quality, and affordability of care.
International Healthcare Week 2026 promises to be an unparalleled convergence of industry expertise and business opportunities, strengthening Southeast Asia's collective capacity in health innovation and delivering lasting impact across the region.
"Thailand is at the heart of Southeast Asia's rapidly growing healthcare market, making it the perfect location to showcase our biosensor technology. WHX Bangkok offered an excellent opportunity to connect with prospective buyers and strengthen relationships with existing partners. This platform aligned seamlessly with our goals of expanding our presence in Asia, reaffirming our leadership in the diagnostic market, and driving sustainable growth in the region." Na Jiwoong, POC Division Head, i-SENS, South Korea.
"Participating in CPHI South East Asia has been an incredible experience for us! This event serves as a dynamic platform to connect with our valued customers, explore emerging market trends, and gain valuable industry insights. Our goal in being part of CPHI South East Asia is to strengthen our presence in the region, build meaningful relationships with customers, and proudly showcase our innovative drug delivery systems, active material science solutions, and services that advance patient care and improve treatment outcomes." Anand Hiremath, Vice President, Aptar Pharma, India.
With the theme "Local & Regional to Global Networking," the event aims to empower companies to scale their businesses from local markets to the wider global stage.
With a focus on addressing the needs of around 700 million Southeast Asia citizens, the event fosters innovation, delivers cutting-edge healthcare solutions, and encourages knowledge transfer and cross-border collaboration among industry leaders, policymakers, and investors.
Thailand - Southeast Asia's Hub for Healthcare Innovation
Thailand's robust infrastructure, supportive regulatory environment, and flourishing innovation ecosystem make it an ideal gateway for Southeast Asia-wide healthcare development. Positioned as a major regional hub, International Healthcare Week 2026 reinforces Thailand's growing role as a centre for healthcare, medical technology, and pharmaceutical development. This premier event offers unparalleled opportunities for forging new partnerships, attracting investments, and driving market expansion throughout the health ecosystem in ASEAN and beyond.
Be Part of International Healthcare Week 2026
The event offers unmatched opportunities to build meaningful partnerships and contribute to shaping the future of healthcare in Southeast Asia and extend global impact. Don't miss the chance to advance your career and position yourself at the forefront of healthcare evolution.
For more information and registration details, please visit https://inthealthcareweek.com/
About Informa Markets
Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world's leading exhibitions organiser, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year. For more information, please visit www.informamarkets.com.
For Media enquiries, please contact:
Gautam Jatwani
Senior Marketing Manager
Informa Markets
Gautam.jatwani@informa.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
International Healthcare Week Returns to Thailand in 2026 with Expanded Industry Reach
